Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Small difference, significant effect: How antibodies influence the defense against infections

06.08.2018

Some autoimmune diseases are successfully treated with monoclonal antibodies (mabs) targeted at inhibiting the release of the inflammatory messenger substance (cytokine) tumor necrosis factor alpha (TNFα). However, TNFα is also important for the defense against pathogenic agents. Researchers at PEI have compared the effects of various mabs for their ability of human immune cells to combat the parasite leishmania. Even a small molecular change (PEGylation) turned out to improve the immune defense against pathogens significantly. The results are reported in Frontiers in Immunology in its online version of 31 July 2018.

Autoimmune diseases are chronic inflammatory diseases in which immune cells erroneously attack the body’s own cells or tissue. In these diseases which, for example, also include rheumatoid arthritis, psoriasis, or chronic inflammatory diseases of the intestine such as Crohn’s disease, TNFα plays an important role. Among other things, it conveys the classic inflammatory symptoms: swelling, redness, and pain.


Monoclonal antibodies (mabs) against TNFα influence the defense against a leishmania infection at different rates.

Source: PEI

However, TNFα is a versatile cytokine which, in its role as a central regulator of the immune system is also important for the defense of pathogenic agents. Thus, there is evidence that the treatment with mabs blocking TNFα involves an increased risk of infectious disease. However, the data obtained up to now are contradictory.

Furthermore, an increased occurrence of the parasitic disease leishmaniosis was reported in patients treated with a particular mab. Leishmaniosis is caused by the single-cell parasite leishmanial transmitted by sand flies. The disease above all occurs in the Mediterranean, tropical regions, and Asia. Around one million people contract the disease world-wide each year.

Do TNFα-blocking mabs differ in their influence on the immune defense of the body? Researchers led by Professor Ger van Zandbergen, head of Division Immunology of the Paul Ehrlich Institut and Dr Katharina Arens have studied the influence of various TNFα-blocking mabs on the immune response of human immune cells against leishmania. The studies were performed by the researchers in vitro – outside the body.

For this purpose, they infected macrophages, certain immune cells of the body which are preferably infected by leishmainia, with the parasite. Then they added different mabs and T-lymphocytes. T-lymphocytes, in their role as important immune cells, are normally able to recognise infected macrophages, to replicate as a result of this contact, and to combat the pathogen directly.

The reactions of the T-cells to the parasite in the presence of the different mabs differed greatly. While some mabs markedly reduced T-lymphocyte activity thus enabling the parasites to replicate, the effect was lower with another mab – and replication of the leishmania was prevented.

In a next step, the researchers of the PEI compared the molecular structure of the mab showing the different action profiles. In doing so, they found that polymer polyethylene glycol (PEG) was the molecule that causes a small but significant difference. It primarily extends the half-life of the effect created by the antibody, since it protects from the body’s own digestion of the antibody: PEGylation – the adherence of the PEG to the mab at defined sites reduces the inhibitory effect of TNFα-blocking mabs on the immune defense against leishmanial.

The researchers conclude from these results that only small PEG modifications of TNFα inhibiting mabs are able to reduce effects that weaken the immune defense. In the researcher’s view, the differences between the mabs with regard to immune defense should be further studied in order to gain insights on the road to effective and even safer medicinal products.

The Paul-Ehrlich-Institut, the Federal Institute for Vaccines and Biomedicines, in Langen near Frankfurt/Main is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and immunological veterinary medicinal products.

Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects. Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the manifold tasks performed at the institute.

The Paul-Ehrlich-Institut, with its roughly 800 members of staff, also has advisory functions nationally (federal government, federal states (Länder)), and internationally (World Health Organisation, European Medicines Agency, European Commission, Council of Europe etc.).

Originalpublikation:

Original publication: Arens K, Filippis C, Kleinfelder H, Goetzee A, Crauwels P, Reichmann G, Waibler Z, Bagola K, van Zandbergen, G (2018): Anti‐TNFα therapeutics differentially affect Leishmania infection of human macrophages. Front. Immunol., 31 July 2018 |
https://doi.org/10.3389/fimmu.2018.01772

Weitere Informationen:

https://www.frontiersin.org/articles/10.3389/fimmu.2018.01772/full - Text of the Publication
https://www.pei.de/EN/information/journalists-press/press-releases/2018/14-small... - This press release on the PEI-Websiste

Dr. Susanne Stöcker | idw - Informationsdienst Wissenschaft

More articles from Life Sciences:

nachricht Switch-in-a-cell electrifies life
18.12.2018 | Rice University

nachricht Plant biologists identify mechanism behind transition from insect to wind pollination
18.12.2018 | University of Toronto

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Data storage using individual molecules

Researchers from the University of Basel have reported a new method that allows the physical state of just a few atoms or molecules within a network to be controlled. It is based on the spontaneous self-organization of molecules into extensive networks with pores about one nanometer in size. In the journal ‘small’, the physicists reported on their investigations, which could be of particular importance for the development of new storage devices.

Around the world, researchers are attempting to shrink data storage devices to achieve as large a storage capacity in as small a space as possible. In almost...

Im Focus: Data use draining your battery? Tiny device to speed up memory while also saving power

The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.

Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...

Im Focus: An energy-efficient way to stay warm: Sew high-tech heating patches to your clothes

Personal patches could reduce energy waste in buildings, Rutgers-led study says

What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

 
Latest News

Pressure tuned magnetism paves the way for novel electronic devices

18.12.2018 | Materials Sciences

New type of low-energy nanolaser that shines in all directions

18.12.2018 | Physics and Astronomy

NASA research reveals Saturn is losing its rings at 'worst-case-scenario' rate

18.12.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>